Intensity Therapeutics7 Nov 2019 12:39
https://www.businesswire.com/news/home/20191107005433/en/Data-Intensity-Therapeutics%E2%80%99-Phase-12-Study-INT230-6
WESTPORT, Conn.--(BUSINESS WIRE)--Intensity Therapeutics, Inc., a clinical-stage biotechnology company developing proprietary intratumoral immunotherapy products to kill tumors and increase immune system recognition of solid cancers, today announced new preliminary data from the ongoing Phase 1/2 clinical study of INT230-6, the Company’s lead product candidate. These data will be presented on Saturday, November 9, in an oral podium presentation at the Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting, being held in National Harbor, MD.